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Serum amyloid A inhibits RANKL-induced osteoclast
formation
Eunseo Oh1, Ha Young Lee1,2, Hak Jung Kim1, Yoo Jung Park1, Jeong Kon Seo3, Joon Seong Park4
and Yoe-Sik Bae1,2,5
When mouse bone marrow-derived macrophages were stimulated with serum amyloid A (SAA), which is a major acute-phase
protein, there was strong inhibition of osteoclast formation induced by the receptor activator of nuclear factor kappaB ligand.
SAA not only markedly blocked the expression of several osteoclast-associated genes (TNF receptor-associated factor 6 and
osteoclast-associated receptor) but also strongly induced the expression of negative regulators (MafB and interferon regulatory
factor 8). Moreover, SAA decreased c-fms expression on the cell surface via shedding of the c-fms extracellular domain. SAA
also restrained the fusion of osteoclast precursors by blocking intracellular ATP release. This inhibitory response of SAA is not
mediated by the well-known SAA receptors (formyl peptide receptor 2, Toll-like receptor 2 (TLR2) or TLR4). These ﬁndings
provide insight into a novel inhibitory role of SAA in osteoclastogenesis and suggest that SAA is an important endogenous
modulator that regulates bone homeostasis.
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INTRODUCTION
Osteoclasts are giant multinucleated cells that are derived from
the monocyte lineage.1 Osteoclasts have a crucial role in bone
homeostasis through their bone resorbing activity by adhering
tightly to the bone surface through interactions with
extracellular matrix proteins.2 Two osteoclastogenic mediators,
macrophage colony-stimulating factor (M-CSF) and receptor
activator of nuclear factor κB ligand (RANKL), induce
osteoclast differentiation.3 Because osteoclasts are the only cells
that resorb bone in the body,2 the blockade of osteoclast
differentiation by inhibiting the action of RANKL or M-CSF
and RANKL can effectively block bone erosion in animal
models.4,5
Serum amyloid A (SAA), which is a major acute-phase
protein that is released into the circulation in response to
infection or injury, is released from liver cells in response to a
pro-inﬂammatory environment.6 Because SAA induces
proinﬂammatory cytokine and chemokine production in
several cell types, such as rheumatoid synoviocytes, intestinal
epithelial cells, monocytes and neutrophils, SAA is considered
to possess cytokine-like properties with immunomodulatory
roles. Previous reports have demonstrated that SAA acts on
several cell surface receptors.7–9 SAA selectively stimulates
formyl peptide receptor 2 (FPR2), resulting in Ca2+ mobiliza-
tion and chemotactic migration.7 SAA was also reported to act
on Toll-like receptor 2 (TLR2) to elicit intracellular signaling,
resulting in G-CSF expression leading to neutrophilia.8
In addition, SAA also has been reported to act on P2X
purinoceptor 7 (P2X7), and activate the NOD-like receptor
family, pyrin domain-containing 3 inﬂammasome.9 However,
the roles of SAA on osteoclast differentiation have not been
examined. In this study, we investigated whether SAA affects
osteoclastogenesis in mouse bone marrow-derived osteoclast
precursors. We also examined whether FPR2 or TLR2/4
are involved in SAA-induced osteoclastogenesis and in the
signaling pathways involved in this process.
MATERIALS AND METHODS
Materials
Human recombinant SAA, murine recombinant M-CSF, human
recombinant M-CSF, and murine RANKL were purchased from
Peprotech (Rocky Hill, NJ, USA). Pam3CSK4 was purchased from
Invitrogen (San Diego, CA, USA). Lipopolysaccharide (LPS) and
oxidized ATP were purchased from Sigma-Aldrich (St. Louis,
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MO, USA). WRWWWW (WRW4) was synthesized from AnyGen
(Gwangju, Korea). Polymyxin B, pertussis toxin, SB203580 and U0126
were purchased from Calbiochem (San Diego, CA, USA). The
APC-Anti-mouse CD115(c-fms) was purchased from eBioscience
(San Diego, CA, USA). TAPI-1 was purchased from Enzo Life Sciences
(Plymouth Meeting, PA, USA). The phospho-ERK, ERK, phospho-
p38 mitogen-activated protein kinase (MAPK), p38 MAPK and
β-actin antibodies were purchased from Cell Signaling Technology
(Beverly, MA, USA).
Osteoclast differentiation and tartrate-resistant acid
phosphatase (TRAP) staining
The mouse bone marrow-derived macrophages (BMDMs; 5× 103 cells
per well of 96 well plate) were differentiated into osteoclasts using
M-CSF (30 ngml− 1) and RANKL (100 ngml− 1), as previously
described.10 Human monocytes were isolated as previously
described.11 The human monocytes were differentiated into macro-
phages by adding M-CSF (30 ngml− 1) for 3 days. The human
macrophages (5× 103 cells per well) were further differentiated into
osteoclasts by adding M-CSF (30 ngml− 1) and RANKL (100 ngml− 1)
for 17 days, as previously described.12 The differentiated cells were
stained for TRAP using an Acid Phosphatase, Leukocyte (TRAP) Kit
(Sigma, San Diego, CA, USA). The TRAP+ multinuclear cells (43
nuclei) with a value 43 were considered to be osteoclasts.
Cell viability assay
The cell viability assay was conducted using the Cell Counting Kit-8
solution (Dojindo, Rockville, MD, USA), as previously described.13
Reverse transcription–PCR analysis
The sequences of the primer used include: RANK: forward,
5′-AGAAGACGGTGCTGGAGTCT-3′, reverse, 5′-TAGGAGCAGTG
AACCAGTCG-3′; TNF receptor-associated factor 6 (TRAF6): forward,
5′-GCCCAGGCTGTTCATAATGT-3′, reverse, 5′-TCGCCCACGTA
CATACTCTG-3′; osteoclast-associated receptor (OSCAR): forward,
5′-CTGCTGGATACGGATCAGCTCCCCAGA-3′, reverse, 5′-CCAAG
GAGCCAGAACCTTCGAAACT-3′; TRAP: forward, 5′-CAGTTGGCA
GCAGCCAAGGAGGAC-3′, reverse, 5′-TCCGRGCTCGGCGATGGA
CCAGA-3′; B lymphocyte-induced maturation protein 1 (Blimp1):
forward, 5′-TTCTTGTGTGGTATTGTCGGGACTT-3′, reverse, 5′-TTG
GGGACACTCTTTGGGTAGAGTT-3′; c-FOS: forward, 5′-AGAGC
GGGAATGGTGAAGAC-3′, reverse, 5′-GCTGCATAGAAGGAACC
GGA-3′; nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1):
forward, 5′-CCAGTATACCAGCTCTGCCA-3′, reverse, 5′-GTGGGA
AGTCAGAAGTGGGT-3′; MafB: forward, 5′-AGTGTGGAGGACC
GCTTCTCT-3′, reverse, 5′-CAGAAAGAACTCAGGAGAGGAGG-3′;
interferon regulatory factor 8 (IRF-8): forward, 5′-CGTGGAAGAC
GAGGTTACGCTG-3′, reverse, 5′-GCTGAATGGTGTGTGTCATA
GGC-3′; and c-fms: forward, 5′-CCAGAGCCCCCACAGATAA-3′,
reverse, 5′-AGCTTGGTGTCTCCACGTTTG-3′. For Reverse
transcription–PCR, 35 PCR cycles were performed at 94 °C (denatura-
tion, 30 s), 55–65 °C (annealing, 30 s) and 72 °C (extension, 1min).
The PCR products were electrophoresed on a 1.5% agarose gel and
visualized by ethidium bromide.
Western blot assay
The cell extracts were prepared by lysing the cells in a buffer
containing 20mM HEPES (pH 7.2), 10% glycerol, 150mM NaCl,
1% Triton X-100, 50mM NaF, 1mM Na3VO4, 10 μgml− 1 leupeptin,
10 μg ml− 1 aprotinin and 1mM PMSF. The western blot analysis was
conducted as previously described.14
Flow cytometry
The osteoclasts or BMDMs were incubated with an anti-murine
CD16/32 antibody to block the Fc receptor-mediated antibody binding
for 20min on ice. The cells were then incubated with an anti-mouse
CD115 (c-fms) antibody to stain the cell surface expression of c-fms.
A FACSCanto II ﬂow cytometer (BD Bioscience, San Jose, CA, USA)
was used to detect the c-fms protein on the cell surface.
Extracellular ATP measurement
To measure the extracellular ATP levels, the mouse BMDMs (5× 103
cells per well) were seeded in 96-well plates and cultured with M-CSF
(30 ngml− 1) and RANKL (100 ngml− 1) in minimum essential
medium alpha with 10% fetal bovine serum containing minimum
essential medium alpha for 3 days at 37 °C and 5% CO2. The cell
culture supernatant was collected after 1 h, and the extracellular ATP
concentration was measured as previously described.15
Statistical analysis
The results are expressed as the mean± s.e. for the data obtained from
the indicated number of experiments. The statistical analysis was
performed using Student’s t-test and analysis of variance.
RESULTS
SAA inhibits osteoclast formation from mouse macrophages
To examine the effects of SAA on osteoclast formation, we
stimulated the BMDMs with SAA in the presence of M-CSF
and RANKL. Osteoclast formation was induced by incubating
the BMDMs with M-CSF plus RANKL, which was identiﬁed
by TRAP staining (Figure 1a). Under these conditions, the
addition of SAA (1 μM) completely inhibited RANKL-induced
osteoclast formation (Figure 1a). The SAA-induced inhibitory
effect on osteoclast formation was concentration dependent
and showed signiﬁcant effects starting at the 10 nM concentra-
tion (Figure 1b). The addition of 100 nM–1 μM SAA almost
completely inhibited osteoclast formation (Figure 1b). Because
the SAA that we used is a recombinant protein expressed from
Escherichia coli, we pretreated cells with an LPS inhibitor
(polymyxin B) prior to SAA addition to test for the possible
involvement of LPS contamination. Polymyxin B pretreatment
did not affect the SAA-induced inhibitory effects on osteoclast
formation (Figure 1c). As a control, LPS completely inhibited
osteoclast formation, which was markedly reversed by
polymyxin B. These results indicate that the inhibitory effects
of SAA on osteoclast formation are not a side effect of LPS
contamination.
We also determined whether SAA blocks osteoclast
formation by inducing cell death in in vitro culture conditions.
In the presence of M-CSF, the BMDMs continuously
proliferated, whereas the addition of RANKL markedly
decreased BMDM proliferation. The BMDMs treated with
RANKL and SAA also exhibited increased proliferation
compared with the cells treated with RANKL alone
(Figure 1d). The results indicate that the inhibitory effects of
SAA on osteoclast formation are not caused by cytotoxicity.
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To examine whether SAA blocked osteoclast formation in
human cells, we tested the effects of SAA on osteoclastogenesis
using human macrophages. The incubation of human macro-
phages with M-CSF and RANKL elicited osteoclast formation
as previously reported.12 However, SAA markedly inhibited the
RANKL-induced osteoclastogenesis of human macrophages
(Figure 1e).
SAA regulates RANKL-induced gene expression
During osteoclast formation, several osteoclast-associated
genes, including TRAF6, OSCAR, and NFATc1, are
upregulated.16 We also found that the RANKL treatment
upregulated the mRNA levels of TRAF6, OSCAR, TRAP, Blimp,
c-FOS and NFATc1 (Figure 2a). However, the addition of SAA
in the presence of RANKL strongly blocked the upregulation of
these osteoclast-associated genes (Figure 2a). RANKL induces
cellular signaling by acting on its cell surface receptor, RANK.17
RANKL-induced osteoclast formation is accompanied by
increased RANK expression.18 We also observed that RANKL
stimulated RANK expression in BMDMs, which was markedly
decreased by SAA (Figure 2a). Another TLR2 agonist,
Pam3CSK4, also strongly decreased RANKL-induced RANK
expression (data not shown). Blimp1 mediates osteoclast
formation by blocking the expression of Bcl6, which inhibits
the expression of osteoclast-associated gene products such as
NFATc1.19 In this study, we also observed that the addition of
RANKL induced Blimp1 upregulation. However, the addition
of SAA in the presence of RANKL strongly blocked Blimp1
upregulation (Figure 2a). The protein levels of the genes that
were downregulated by SAA, such as RANK and TRAF6, were
also markedly decreased (Figure 2b).
Recently, some negative regulators, including MafB and
IRF-8, that mediate the inhibition of osteoclast formation
have been reported. RANKL downregulates these negative
regulators.20,21 We also showed that the stimulation of BMDMs
with RANKL downregulated MafB and IRF-8 (Figure 2c). The
addition of SAA markedly reversed the reduced expression of
MafB and IRF-8 (Figure 2c).
Figure 1 SAA blocks RANKL-induced osteoclastogenesis. (a) Mouse BMDMs were stimulated with SAA (1 μM) in the presence of M-CSF
(30 ngml−1) and RANKL (100 ngml−1) for 4 days. (b) Mouse BMDMs were stimulated with various concentrations of SAA (0, 1, 10, 100,
and 1000nM) in the presence of M-CSF (30 ngml−1) and RANKL (100 ngml−1) for 4 days. (c) Mouse BMDMs were pre-incubated with
polymyxin B (10 ngml−1) prior to SAA (1 μM) and LPS (1 μgml−1) treatment in the presence of M-CSF (30 ngml−1) and RANKL
(100 ngml−1) for 4 days. (d) Mouse BMDMs were stimulated with SAA (1 μM) in the presence of M-CSF (30 ngml−1) and RANKL
(100 ngml−1) for 0, 1, 2, 3 and 4 days. (e) Human monocyte-derived macrophages were stimulated with 1 μM SAA in the presence of
M-CSF (30 ngml−1) and RANKL (100 ngml−1) for 17 days. After adding the CCK-8 assay solution, the OD was measured at 450 nm (d). All
cells were stained using TRAP staining solution. The TRAP+ MNCs (43 nuclei) were considered to be osteoclasts (a–c, e). The data are
expressed as the mean± s.e. of an experiment in duplicate (b–e). The data in the panels are representative of two (e) or three (b–d)
independent experiments. *Po0.05 and **Po0.01. BMDM, bone marrow-derived macrophage; M-CSF, macrophage colony-stimulating factor;
MNC, multinuclear cell; NS, not signiﬁcant; NT, not treated; RANKL, receptor activator of nuclear factor κB ligand; SAA, serum amyloid A.
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SAA decreases c-fms expression via ectodomain shedding by
tumor necrosis factor-α converting enzyme
Along with RANK, c-fms, a receptor for M-CSF, is known to
be crucial for osteoclast formation.22 Osteoclast-like multi-
nuclear cell formation was reported to be blocked by co-culture
with anti-M-CSF or anti-c-fms antibodies.23 Moreover, RANK
expression is dependent on M-CSF signaling via c-fms.24 In
this study, we investigated the role of SAA in c-fms expression
during osteoclast formation. When SAA was added in the
presence of RANKL, the levels of the cell surface c-fms protein
were dramatically decreased compared with the RANKL-
treated group (Figure 3a). The expression of c-fms can be
rapidly reduced by shedding of the extracellular domain, and
this proteolytic cleavage is mediated by tumor necrosis factor-α
converting enzyme (TACE), which is also known as a
disintegrin and metalloproteinase 17 (ADAM17).25 TLR
ligand-mediated downregulation of c-fms is consistently
blocked by a TACE inhibitor.26 Surprisingly, the c-fms expres-
sion levels that were downregulated from 82.6 to 1.75% within
1 h were recovered to 78.2% by TAPI-1 (TACE inhibitor)
treatment (Figure 3a). TACE-mediated ectodomain shedding is
known to be activated by ERK and p38 MAPK.27,28 Previously,
SAA was reported to stimulate ERK and p38 MAPK
phosphorylation.29 We tested whether SAA stimulated the
activation of ERK and p38 MAPK during osteoclastogenesis
by measuring the SAA-induced ERK and p38 MAPK phos-
phorylation in the presence or absence of RANKL. RANKL is
known to induce ERK and p38 MAPK phosphorylation during
osteoclast formation.1 We also observed that the stimulation of
BMDMs with RANKL elicited ERK and p38 MAPK phosphor-
ylation (Figure 3b). Moreover, SAA further stimulated ERK
and p38 MAPK phosphorylation in the presence of RANKL
(Figure 3b). To understand the role of ERK and p38 MAPK in
SAA-induced c-fms shedding, we measured the surface expres-
sion levels of c-fms in the presence of U0126 (a MEK inhibitor)
or SB203580 (a p38 MAPK inhibitor). Neither U0126 nor
SB203580 affect the SAA-induced reduction in c-fms expres-
sion (Figure 3c). However, treatment with both U0126 and
SB203580 markedly reversed the SAA-induced downregulation
of c-fms expression (Figure 3c). The results suggest that the
two MAPK (ERK and p38 MAPK) activities are both required
for the downregulation of c-fms by SAA.
FPR2, TLR2 and TLR4 are not involved in the SAA-induced
inhibitory effects on osteoclast formation
Several cell surface receptors, including FPR2, TLR2 and TLR4,
have been reported to act as target molecules for SAA
action.20,21,30 To test whether FPR2 has a role in the
SAA-induced inhibitory effects on osteoclast formation, we
ﬁrst preincubated the BMDMs with an FPR2-selective antago-
nist, WRW4,31 prior to SAA addition. The inhibitory effects of
SAA on osteoclast formation were not reversed by WRW4
(Figure 4a). FPR2 activation induces cellular signaling through
pertussis toxin-sensitive G-protein(s).32 The preincubation
with pertussis toxin prior to SAA addition in the presence of
RANKL did not affect the inhibitory effects of SAA on RANKL-
induced osteoclastogenesis in the BMDMs (Figure 4b). These
results indicate that FPR2 does not mediate the SAA-induced
inhibition of RANKL-induced osteoclastogenesis. We next
tested whether TLR2 or TLR4 has a role. First, we conﬁrmed
that SAA, LPS (TLR4 agonist) and Pam3CSK4 (TLR2 agonist)
completely inhibited osteoclast formation. The Pam3CSK-
induced inhibitory effect on osteoclast formation was reversed
in the BMDMs derived from the TLR2-deﬁcient mice
(Figure 4c). However, the SAA-induced inhibitory effect was
not reversed upon TLR2-deﬁciency (Figure 4c). In the BMDMs
isolated from the TLR4 mutant mice (C3H/HeJ), the inhibitory
effect on osteoclast formation was reversed by LPS, but not by
SAA (Figure 4d). The results indicate that the SAA-induced
inhibitory effect on osteoclast formation is not mediated by
FPR2, TLR2 or TLR4.
SAA inhibits RANKL-induced ATP release and the
expression of RANKL-induced fusogenic genes
RANKL-induced osteoclast formation was recently reported to
be mediated by the activation of the adenosine receptor, which
is induced by the generation of adenosine from ATP through
apyrase and hexokinase activity.33 The extracellular ATP level
can be increased by opening the P2X7 receptor on the cell
surface.33 We also found that RANKL-induced osteoclast
formation was almost completely inhibited by the addition of
oxidized ATP, a P2X7 antagonist (data not shown), supporting
the idea that RANKL-induced osteoclast formation is mediated
by ATP release. We also observed that the stimulation of
Figure 2 SAA regulates RANKL-induced gene expression during
osteoclastogenesis. (a–c) Mouse BMDMs were stimulated with SAA
(1 μM) in the presence of M-CSF (30 ngml−1) and RANKL
(100 ngml−1) for 3 days. (a, c) The cells were harvested to prepare
the RNA. RT-PCR was performed using speciﬁc primers for RANK,
TRAF6, OSCAR, TRAP, Blimp1, c-FOS, NFATc1, MafB, IRF-8
and GAPDH. (b) The cells were harvested, and Western
blot analysis was conducted using anti-RANK, anti-TRAF6 and
anti-β-actin antibodies. The results shown are representative of
three independent experiments (a–c). BMDM, bone marrow-derived
macrophage; M-CSF, macrophage colony-stimulating factor; NT, not
treated; RANKL, receptor activator of nuclear factor κB ligand;
RT-PCR, reverse transcription–PCR; SAA, serum amyloid A.
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osteoclast precursor cells with M-CSF and RANKL strongly
increased the extracellular ATP levels (Figure 5a). SAA addition
almost completely inhibited the RANKL-induced ATP release
(Figure 5a).
For the proper formation of functional osteoclasts, osteoclast
precursors need to fuse together to generate immature and
mature osteoclasts.34 Several genes, such as dendritic cell-speciﬁc
transmembrane protein (DC-STAMP), osteoclast stimulatory
transmembrane protein (OC-STAMP) and Atp6v0d2, have been
reported to regulate the fusion process during osteoclast
formation.34–36 We also found that the stimulation of osteoclast
precursors with M-CSF and RANKL strongly increased the
mRNA levels of DC-DTAMP, OC-STAMP and Atp6v0d2.
The addition of SAA markedly reduced the levels of these
RANKL-induced osteoclast fusion-associated genes (Figure 5b).
The results suggest that SAA may inhibit cell fusion by
downregulating the fusogenic genes.
DISCUSSION
Because osteoclasts are the only cells that mediate bone
resorption and RANKL induces osteoclast differentiation, the
identiﬁcation of endogenous molecules that inhibit osteoclast
differentiation by blocking the action of RANKL is of interest.
In this study, we demonstrate that SAA, an endogenous acute
phase reactant, strongly inhibits RANKL-induced osteoclast
formation, suggesting a novel functional role for SAA in
osteoclastogenesis. In this study, we also showed that SAA
strongly blocked the fusion of osteoclasts (Figure 5). Previously,
LPS has been reported to inhibit osteoclastogenesis from
freshly isolated osteoclast precursors, but it was shown to
stimulate osteoclast formation from RANKL-primed osteoclast
precursors.37 We also tested the effect of SAA at the different
time points of osteoclast differentiation and found that
SAA strongly blocked osteoclast formation and fusion at the
different time points (Figures 1 and 5 and data not shown).
Figure 3 SAA stimulates c-fms shedding by TACE, which is dependent on ERK and p38 MAPK activity. (a) Mouse BMDMs were
pre-incubated with TAPI-1 (20 μM) for 1 h prior to the SAA (1 μM) treatment. The c-fms levels on the cell surface were determined by ﬂow
cytometry using an anti-c-fms antibody. (b) Mouse BMDMs were stimulated with SAA (1 μM) in the presence of M-CSF (30 ngml−1),
RANKL (100 ngml−1) or M-CSF (30 ngml−1) and RANKL (100 ngml−1) for 0, 2, 5, 10, 30 and 60min. The phosphorylated ERK and
p38 MAPK levels were determined by immunoblotting using anti-phospho-ERK and anti-phospho-p38 MAPK antibodies. (c) Mouse
BMDMs were pre-incubated for 1 h with U0126 (40 μM; top), SB203580 (20 μM; middle), or U0126 (40 μM) and SB203580 (20 μM;
bottom) prior to the SAA (1 μM) treatment. The c-fms levels on the cell surface were determined by ﬂow cytometry using an anti-c-fms
antibody. The results shown are representative of three independent experiments (a–c). BMDM, bone marrow-derived macrophage; M-CSF,
macrophage colony-stimulating factor; NT, not treated; RANKL, receptor activator of nuclear factor κB ligand; SAA, serum amyloid A.
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Figure 4 The inhibitory effects of SAA on RANKL-induced osteoclast formation are independent of FPR2, TLR2 or TLR4. (a, b) Mouse
BMDMs were pre-incubated with WRW4 (60 μM) or PTX (100 ngml−1) prior to the SAA (1 μM) treatment in the presence of M-CSF
(30 ngml−1) and RANKL (100 ngml−1) for 4 days. (c, d) BMDMs were isolated from WT (C57BL/6), TLR2 KO (C57BL/6 background),
TLR4 WT (C3H/HeN), and TLR4 mutant (C3H/HeJ) mice. The cells were stimulated with SAA (1 μM), Pam3CSK4 (1 μgml−1), or LPS
(1 μgml−1) in the presence of M-CSF (30 ngml−1) and RANKL (100 ngml−1) for 4 days. (a–d) All cells were stained using the TRAP
staining solution. The TRAP+ MNCs (43 nuclei) were considered to be osteoclasts. The data are expressed as the mean± s.e. of three
independent experiments performed in duplicate. *Po0.05 and ***Po0.001. BMDM, bone marrow-derived macrophage; M-CSF,
macrophage colony-stimulating factor; MNC, multinuclear cell; NS, not signiﬁcant; NT, not treated; RANKL, receptor activator of nuclear
factor κB ligand; SAA, serum amyloid A.
Figure 5 SAA decreases the RANKL-induced intracellular ATP release and fusogenic gene expression during osteoclastogenesis. (a) Mouse
BMDMs were stimulated with SAA (1 μM) and oATP (200 μM) in the presence of M-CSF (30 ngml−1) and RANKL (100 ngml−1) for
3 days. The extracellular ATP concentrations were determined by a bioluminescence assay. (b) Mouse BMDMs were stimulated with SAA
(1 μM) in the presence of M-CSF (30 ngml−1) and RANKL (100 ngml−1) for 3 days. The cells were harvested to prepare the RNA. RT-PCR
was performed using speciﬁc primers for DC-STAMP, OC-STAMP, Atp6v0d2 and GAPDH. The results shown are representative of three
independent experiments. The data are expressed as the mean± s.e. of an experiment in duplicate (a). The data in the panel are
representative of three independent experiments (a). *Po0.05 and **Po0.01. BMDM, bone marrow-derived macrophage; M-CSF,
macrophage colony-stimulating factor; NS, not signiﬁcant; NT, not treated; oATP, oxidized ATP; RANKL, receptor activator of nuclear
factor κB ligand; SAA, serum amyloid A.
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We demonstrate that SAA strongly inhibits RANKL-induced
osteoclast formation in a concentration-dependent manner,
showing maximal activity at ~ 1 μM (Figure 1b). We demon-
strate that neither of the cell surface receptors FPR2 or
TLR2/TLR4 have a role in this inhibition (Figure 4). Both an
FPR2 antagonist and a Gi-protein inhibitor, pertussis toxin,
failed to inhibit the inhibitory effects of SAA on osteoclast
formation (Figure 4). We were also able to rule out the
involvement of TLR2 or TLR4 using TLR2-deﬁcient mice or
TLR4 mutant mice (Figure 4). Because other receptors, such
as CD36 and P2X7, have been reported to mediate the
SAA-induced cellular signaling and responses,9,29 we attempted
to examine whether these two receptors were involved in
the inhibitory effect of SAA on osteoclast formation.
Unfortunately, we could not test the involvement of these
receptors because both CD36 and P2X7 are required for
RANKL-induced osteoclastogenesis. The inhibition of
P2X7 with oxidized ATP completely blocked RANKL-induced
osteoclastogenesis (data not shown). The information
regarding speciﬁc receptor(s) that mediate the inhibitory effect
of SAA on RANKL-induced osteoclast formation should be
clariﬁed in future work.
Regarding the mechanism of the inhibitory effect of SAA
RANKL-induced osteoclastogenesis, we found that SAA blocked
osteoclast formation by modulating RANKL-induced gene
expression (Figure 2). Fusogenic gene expression in osteoclasts
was also markedly decreased by SAA (Figure 5b). These ﬁndings
suggest that SAA may block the RANKL-RANK-induced
signaling pathway that leads to osteoclast formation. The activity
of c-fms, an M-CSF receptor, is also crucially required for the
proper generation of osteoclasts from precursor cells by
RANKL.24 Previously, the TLR ligand-mediated downregulation
of c-fms from the cell surface was reported to inhibit
osteoclastogenesis.26 Here, we also observed that SAA induced
the shedding of the extracellular domain of c-fms (Figure 3a).
This TACE-mediated proteolytic cleavage of the c-fms ectodo-
main was dependent on ERK and p38 MAPK activation
(Figure 3c). These results provide a plausible explanation for
the high levels of ERK and p38 MAPK phosphorylation induced
by SAA in the presence of RANKL, which had been difﬁcult to
reconcile with the fact that RANKL-induced ERK and p38
MAPK phosphorylation are required for osteoclast
differentiation.1 Our results suggest that SAA may block c-fms
signaling by activating ERK and p38 MAPK to stimulate c-fms
ectodomain shedding, thus inhibiting osteoclast formation.
During the pathological process of rheumatoid arthritis, SAA
levels were reported to be increased in the synovial ﬂuid and
SAA was reported to recruit inﬂammatory cells into the
synovium, leading to increased inﬂammation in the area.38
However, we demonstrate that SAA blocks osteoclast
differentiation from BMDMs. This ﬁnding suggests that the
increased SAA levels in the synovial ﬂuid may promote negative
feedback activity in terms of bone homeostasis. The increased
SAA levels in the synovial ﬂuid may block osteoclast formation,
ultimately resulting in the inhibition of bone resorption.
Although SAA has been reported to mediate a proinﬂammatory
response by producing proinﬂammatory cytokines, a previous
report demonstrated that SAA inhibits fever and interleukin-
1β- or tumor necrosis factor-α-induced prostaglandin E2
production in vivo.39 The report supports the idea for a
possible feedback relationship between SAA and inﬂammatory
cytokines such as tumor necrosis factor-α and RANKL.
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